ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34109 results sorted by trial registration date.
  • Effect of BMB-101 on seizure frequency and safety in people with absence seizures

    The purpose of this study is to determine whether BMB-101 can reduce absence seizures and whether it is safe and well tolerated in adults participants aged 18-65. Researchers expect that BMB-101 may reduce absence seizures compared with each participant’s seizure activity before treatment. Participants will receive increasing doses of BMB-101, as tolerated, and brain-wave recordings (EEGs) will be used to measure changes in seizure activity. The study will also assess quality of life, sleep, memory, attention and thinking abilities.

  • TAILORs: Time of Administration of Immunotherapy Leading to Optimal Results in patients with advanced or metastatic cancers of the lung, kidney and bladder and melanoma.

    In this research project, we will investigate if administering immunotherapy in the morning (before 11am) versus administration in the afternoon (after 12pm) plays any role in effectiveness and side effects of therapy. Who is it for? You may be eligible for this study if you are an adult with advanced or metastatic cancers of the lung, kidney, bladder or melanoma. Study details Participants will be randomly allocated to receive their standard immunotherapy based treatment either early or later in the day for at least the first 3 months of treatment. Data on response rates, survival and side effects will be collected. It is hoped that findings from this study will help inform clinicians as to how best to deliver immunotherapy to patients.

  • The feasibility of community-informed future food development using heart-healthy plant bioactives in older adults (CARDI-Boost Study)

    This study aims to test whether daily CARDI-Boost consumption is practical, acceptable, and safe for adults at risk of heart disease. We expect to learn if participants can stick with the product, find it suitable for their lifestyle, and tolerate it without major side effects. The design is a single-arm, four-week feasibility trial with 19 participants who will consume one portion of CARDI-Boost each day. Outcomes include adherence, acceptability, tolerability, retention, and exploratory measures such as blood markers. The results will guide whether a larger efficacy trial is warranted in the future.

  • Effects of a remotely-delivered self-directed weight loss diet and exercise program for older adults with knee osteoarthritis and overweight or obesity who live in regional, rural, or remote areas

    Knee osteoarthritis causes pain and difficulty with everyday activities, and people living outside major cities may have limited access to treatment and support. This study aims to find out whether an online weight loss and exercise program can reduce knee pain and improve everyday physical function. We will randomly assign 260 adults aged 65 years or older, who have knee osteoarthritis and overweight or obesity and live in regional, rural or remote Australia, to receive either the program or access to a general information website. The program provides guidance on losing weight using meal replacements, exercises to do at home, and online tools and support. We will compare the groups after six and twelve months to assess the program’s benefits and whether these are maintained over time.

  • Thinking Outside the Lunchbox: societal value of a school lunch program in Australian primary schools (pilot)

    This project will test a new approach to school-based health promotion; an inclusive, equitable school-lunch program that provides fuel for learning, social environments for connection, and teaches children about food systems. The research will compare school-provided lunch programs to quantify their effectiveness, scalability, sustainability, financial viability and societal value. It will develop a sustainable business model using holistic assessment of child learning and wellbeing, environmental sustainability, and economic outcomes. This will drive systems change to support all Australian families by transforming how schools feed children and teach them about food.

  • Evaluation of subcutaneous injections of benzathine penicillin G for prevention of recurrent cellulitis

    Admissions for recurrent cellulitis represent a significant burden to the healthcare system. One strategy for prevention includes the use of prophylactic antibiotics, commonly oral penicillin. There is increasing evidence that subcutaneous administration of high doses of benzathine penicillin G (also known as SCIP), as an alternative to intramuscular administration is effective, well tolerated and achieves favourable serum concentrations. This is an unblinded, non-randomised, opt-in, open-label phase IIa clinical trial to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneous BPG for the prevention of cellulitis. The goal is to provide a potential alternative method of prophylaxis for recurrent cellulitis. We hypothesis that SCIP will be a safe and tolerable alternative for cellulitis prophylaxis.

  • LIGHTWELL-NT: A randomised, participant-blinded, sham-controlled trial of repeated whole body narrowband UVB (ultraviolet B) exposure on wellbeing and systemic physiology in healthy adults.

    Narrowband UVB is an established dermatologic phototherapy modality (6, 7). Human studies show systemic biological effects beyond the treated epidermis, including reproducible increases in serum 25-hydroxyvitamin D (4), changes in circulating immune-cell phenotypes (5), a small healthy-volunteer signal for mood improvement with an IL-6 decrease (2, 9), and a pilot healthy-human signal for gut microbiome change after repeated skin exposure (3). A 2026 observational dermatology cohort also reported improved sleep and fatigue during NB-UVB treatment (8). These findings are suggestive, not definitive: most studies are small, non-sham-controlled, conducted in patient populations, or not designed around wellbeing as a primary outcome (1, 10, 11). The central question is therefore whether repeated whole-body NB-UVB causes a measurable improvement in wellbeing beyond treatment ritual, attention, expectancy and ordinary environmental exposure. The study uses a sham cabinet condition rather than a no-treatment control, because subjective wellbeing outcomes are highly vulnerable to expectancy. The previous bright-visible-light comparator has been removed for feasibility; consequently, the sham must match visible and contextual cues as closely as practicable so that the principal contrast is presence versus absence of biologically active UVB. STUDIES REFERENCED: 1. Topp CW, The WHO-5 Well-Being Index: a systematic review. 2015. 2. Makkonen T et al. Narrow-band ultraviolet B exposures improve mood in healthy individuals differently depending on chronotype. 2019. 3. Bosman ES et al. Skin exposure to narrow band ultraviolet B light modulates the human intestinal microbiome. 2019. 4. Hart PH et al. A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: the PhoCIS study. 2018. 5. Trend S et al. Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome. 2019. 6. Kaur HS et al. Narrow-band UVB phototherapy—Australian consensus-based recommendations. Australas J Dermatol. 2022. 7. Goulden V et al. British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022. 2022. 8. Kaya HE et al. Effects of phototherapy on sleep, fatigue and quality of life in dermatology patients: a pilot study. 2026. 9. Felis-Giemza A et al. Narrow-band ultraviolet B radiation induces the expression of beta-endorphin in human skin in vivo. 2016. 10. Cella D et al. PROMIS adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019. 11. Weinfurt KP et al. Development and initial validation of the PROMIS Sexual Function and Satisfaction Measures version 2.0. J Sex Med. 2015.

  • Safety and ease of use of a heat-activated gel mixed with donor bone to rebuild jawbone during dental implant surgery, without a barrier membrane

    When a dental implant is placed, part of the implant surface is often left without bone covering it. The usual repair packs bone graft particles into the gap and covers them with a membrane, which can be fixed with tacks or screws and is technically demanding. Tegenix is a new synthetic gel that is liquid at room temperature and sets at body temperature. Mixed with donor bone particles, it is designed to hold the graft in place without a membrane, and it dissolves within about 30 days. This is the first study of Tegenix in people. It will check whether Tegenix mixed with donor bone is safe and practical to use when repairing these bone gaps during implant surgery. Ten adults having implant surgery at one specialist periodontal practice in Perth will receive the treatment (up to 15 if participants need to be replaced). The first 3 are treated one at a time, with an independent safety review before more people join. Participants are followed for about 20 months. At about 6 months, when the implant is uncovered, the new bone is measured, scanned and sampled. There is no comparison group; results will be described rather than statistically tested.

  • Integration of ultrasound to assess progress in labour: a randomised controlled trial. The primary objective of this study is to demonstrate that the use of ultrasound to monitor progress in labour will reduce the rate of intrapartum pyrexia amongst nulliparous singleton women undergoing IOL at term.

    Assessment of labour progress in pregnant women who are undergoing induction of labour is traditionally performed using digital vaginal examinations that can be uncomfortable and may contribute to infection risk during labour. Recent research suggests that ultrasound may be a reliable alternative to assess labour progress. This randomised clinical trial aims to determine whether using ultrasound can be used instead of digital vaginal examinations to assess the progress of labour; has an impact on discomfort and anxiety during labour assessments or has an effect on women's birth experience; reduces fever during labour and reduces infection-related complications.

  • An observational study comparing the autonomic nervous system and blood markers in people with heart symptoms but no major coronary artery blockages, people with coronary artery blockages, and healthy volunteers

    INFO-NOCA study aims to advance understanding of heart artery conditions that can cause heart attack–like symptoms, and even heart attacks, in the absence of cholesterol-related blockages, the most common cause of coronary events. Collectively referred to as non-obstructive coronary artery (NOCA) diseases, these conditions remain poorly understood and are often under-recognised in clinical practice. By integrating detailed clinical data, non-invasive assessments of autonomic (nerve) and vascular function, and analysis of novel blood-based biomarkers, this project seeks to uncover the biological mechanisms underlying persistent symptoms and disease progression. The study will also establish a comprehensive biobank and identify potential biomarkers to support more personalised approaches to diagnosis and management in the future. This research is conducted by a collaborative team at the South Australian Health and Medical Research Institute (SAHMRI), the Adelaide University, the Royal Adelaide Hospital (RAH), and The Queen Elizabeth Hospital (QEH), led by Principal Investigator Professor Peter Psaltis, an Interventional Cardiologist. Recruitment will occur through the RAH and QEH, with study procedures undertaken at SAHMRI and the Adelaide University Clinical Trials Laboratory at the Bonython Jubilee Building on Frome Road.

Tags:
  • Finding clinical trials